董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William J. Newell | 男 | Director | 62 | 未披露 | 未持股 | 2020-05-01 |
| Grant E. Pickering | 男 | President, Chief Executive Officer and Director | 52 | 1445.89万美元 | 220.59 | 2020-05-01 |
| Patrick Enright | 男 | Director | 58 | 未披露 | 未持股 | 2020-05-01 |
| Halley Gilbert | 女 | Director | 50 | 49.05万美元 | 9.08 | 2020-05-01 |
| Peter Hirth | -- | Director | 68 | 未披露 | 未持股 | 2020-05-01 |
| Rob Hopfner | -- | Director | 47 | 未披露 | 未持股 | 2020-05-01 |
| Peter Hirth | 男 | Director | 68 | 36.27万美元 | 未持股 | 2020-05-01 |
| Moncef Slaoui | 男 | Chairman of the Board | 60 | 4.50万美元 | 未持股 | 2020-05-01 |
| Robert Hopfner | 男 | Director | 47 | 未披露 | 未持股 | 2020-05-01 |
| Heath Lukatch | 男 | Director | 53 | 47.80万美元 | 8.33 | 2020-05-01 |
| Kurt von Emster | 男 | Director | 52 | 未披露 | 未持股 | 2020-05-01 |
| Patrick Heron | 男 | Director | 49 | 未披露 | 未持股 | 2020-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jane Wright Mitchell | 女 | General Counsel | 51 | 71.32万美元 | 未持股 | 2020-05-01 |
| Grant E. Pickering | 男 | President, Chief Executive Officer and Director | 52 | 1445.89万美元 | 220.59 | 2020-05-01 |
| Andrew Guggenhime | 男 | Chief Financial Officer and Chief Business Officer | 51 | 607.29万美元 | 90.97 | 2020-05-01 |
| Jim Wassil | 男 | Chief Operating Officer | 50 | 581.00万美元 | 63.92 | 2020-05-01 |
| Paul Sauer | 男 | Senior Vice President, Process Development and Manufacturing | 59 | 未披露 | 未持股 | 2020-05-01 |
| Jeff Fairman | 男 | Vice President, Research | 56 | 未披露 | 未持股 | 2020-05-01 |
董事简历
中英对照 | 中文 | 英文- William J. Newell
-
WilliamJ.Newell自2013年11月以来一直担任我们的董事会成员。Newell自2009年2月起担任Sutro Biopharma（一家生物技术公司）首席执行官。2006年1月至2007年8月，Newell先生担任Aerovance，Inc.的总裁兼执行Vice President，该公司是一家由风险投资支持的公司，开发呼吸道疾病的临床资产。Newell先生拥有达特茅斯学院（Dartmouth College）的政府学学士学位和密歇根大学（University of Michigan）的法学博士学位。
William J. Newell has served on our board of directors since November 2013. Since February 2009 Mr. Newell has served as Chief Executive Officer at Sutro Biopharma, a biotechnology company. From January 2006 to August 2007 Mr. Newell served as President and as Executive Vice President at Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell holds an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan. - WilliamJ.Newell自2013年11月以来一直担任我们的董事会成员。Newell自2009年2月起担任Sutro Biopharma（一家生物技术公司）首席执行官。2006年1月至2007年8月，Newell先生担任Aerovance，Inc.的总裁兼执行Vice President，该公司是一家由风险投资支持的公司，开发呼吸道疾病的临床资产。Newell先生拥有达特茅斯学院（Dartmouth College）的政府学学士学位和密歇根大学（University of Michigan）的法学博士学位。
- William J. Newell has served on our board of directors since November 2013. Since February 2009 Mr. Newell has served as Chief Executive Officer at Sutro Biopharma, a biotechnology company. From January 2006 to August 2007 Mr. Newell served as President and as Executive Vice President at Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell holds an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan.
- Grant E. Pickering
-
GrantE.Pickering是我们的联合创始人，自2013年11月以来担任我们的总裁兼首席执行官，并担任我们的董事会成员。2013年5月至2015年4月，皮克林先生担任生物技术公司Atreca，Inc.的战略顾问。加入Vaxcyte公司之前，他曾担任Mymetics Corporation（传染病病毒体疫苗开发商）的首席执行官。在此之前，皮克林先生是风险投资公司凯鹏华盈（Kleiner Perkins）的常驻高管，也是生物制药公司Dendreon Corporation（McKinsey）的运营高级副总裁。Pickering自2008年3月起担任Juvaris Biotherapeutics，Inc.（一家生物制药公司）首席执行官。Pickering先生拥有Penn State University的市场营销学士学位和Georgetown University的工商管理硕士学位。
Grant E. Pickering is our co-founder and has served as our President and Chief Executive Officer and as a member of our board of directors since November 2013. From May 2013 to April 2015 Mr. Pickering served as Strategic Advisor at Atreca, Inc., a biotechnology company. Prior to joining Vaxcyte, he was Chief Executive Officer of Mymetics Corporation, a developer of virosomal vaccines for infectious diseases. Prior to that, Mr. Pickering was an Executive-in-Residence at Kleiner Perkins, a venture capital firm, and Senior Vice President of Operations of Dendreon Corporation, a biopharmaceutical company. Since March 2008 Mr. Pickering has served as Chief Executive Officer of Juvaris BioTherapeutics, Inc., a biopharmaceutical company. Mr. Pickering holds a B.S. in Marketing from Penn State University and an M.B.A. from Georgetown University. - GrantE.Pickering是我们的联合创始人，自2013年11月以来担任我们的总裁兼首席执行官，并担任我们的董事会成员。2013年5月至2015年4月，皮克林先生担任生物技术公司Atreca，Inc.的战略顾问。加入Vaxcyte公司之前，他曾担任Mymetics Corporation（传染病病毒体疫苗开发商）的首席执行官。在此之前，皮克林先生是风险投资公司凯鹏华盈（Kleiner Perkins）的常驻高管，也是生物制药公司Dendreon Corporation（McKinsey）的运营高级副总裁。Pickering自2008年3月起担任Juvaris Biotherapeutics，Inc.（一家生物制药公司）首席执行官。Pickering先生拥有Penn State University的市场营销学士学位和Georgetown University的工商管理硕士学位。
- Grant E. Pickering is our co-founder and has served as our President and Chief Executive Officer and as a member of our board of directors since November 2013. From May 2013 to April 2015 Mr. Pickering served as Strategic Advisor at Atreca, Inc., a biotechnology company. Prior to joining Vaxcyte, he was Chief Executive Officer of Mymetics Corporation, a developer of virosomal vaccines for infectious diseases. Prior to that, Mr. Pickering was an Executive-in-Residence at Kleiner Perkins, a venture capital firm, and Senior Vice President of Operations of Dendreon Corporation, a biopharmaceutical company. Since March 2008 Mr. Pickering has served as Chief Executive Officer of Juvaris BioTherapeutics, Inc., a biopharmaceutical company. Mr. Pickering holds a B.S. in Marketing from Penn State University and an M.B.A. from Georgetown University.
- Patrick Enright
-
Patrick Enright自2015年7月以来一直担任我们的董事会成员。Enright自2006年1月起担任Longitude Capital Management（一家梦百合风险投资公司）总经理。恩赖特先生目前担任临床阶段生物制药公司Aimmune治疗公司、临床阶段制药公司AptinyxInc.和制药公司Jazz Pharmaceuticals plc的董事会成员，以及私营生命科学公司的董事会成员。Enright先生拥有斯坦福大学（Stanford University）生物科学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
Patrick Enright has served as a member of VeraDermics, Incorporated board of directors since December 2024. Mr. Enright has served as a Managing Director of Longitude Capital Management Co., LLC, a healthcare venture capital firm co founded by Mr. Enright, since 2006. Previously, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital firm, where he co led the life sciences investment practice, and served in various senior executive positions at Valentis Inc., Boehringer Mannheim Pharmaceuticals Corp. and Sandoz Inc. Mr. Enright is currently a member of the board of directors of BioAge Labs, Inc., Jazz Pharmaceuticals PLC, Vera Therapeutics, Inc. and Zenas BioPharma, Inc., and has served on such boards since February 2024, January 2012, October 2020 and November 2022, respectively. Mr. Enright also served on the board of directors of Aptinyx Inc. from March 2016 to December 2022. Mr. Enright received his B.S. in Biological Sciences from Stanford University and his M.B.A. from the Wharton School of the University of Pennsylvania. - Patrick Enright自2015年7月以来一直担任我们的董事会成员。Enright自2006年1月起担任Longitude Capital Management（一家梦百合风险投资公司）总经理。恩赖特先生目前担任临床阶段生物制药公司Aimmune治疗公司、临床阶段制药公司AptinyxInc.和制药公司Jazz Pharmaceuticals plc的董事会成员，以及私营生命科学公司的董事会成员。Enright先生拥有斯坦福大学（Stanford University）生物科学学士学位和宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
- Patrick Enright has served as a member of VeraDermics, Incorporated board of directors since December 2024. Mr. Enright has served as a Managing Director of Longitude Capital Management Co., LLC, a healthcare venture capital firm co founded by Mr. Enright, since 2006. Previously, Mr. Enright was a Managing Director of Pequot Ventures, a venture capital firm, where he co led the life sciences investment practice, and served in various senior executive positions at Valentis Inc., Boehringer Mannheim Pharmaceuticals Corp. and Sandoz Inc. Mr. Enright is currently a member of the board of directors of BioAge Labs, Inc., Jazz Pharmaceuticals PLC, Vera Therapeutics, Inc. and Zenas BioPharma, Inc., and has served on such boards since February 2024, January 2012, October 2020 and November 2022, respectively. Mr. Enright also served on the board of directors of Aptinyx Inc. from March 2016 to December 2022. Mr. Enright received his B.S. in Biological Sciences from Stanford University and his M.B.A. from the Wharton School of the University of Pennsylvania.
- Halley Gilbert
-
Halley Gilbert自2020年4月以来一直担任我们的董事会成员。2008年至2020年2月，吉尔伯特女士曾在生物制药公司IronwoodPharmaceuticals，Inc.担任多个职位，包括2019年3月至2020年2月担任高级副总裁，企业发展和首席行政官，担任高级副总裁，2014年至2019年3月担任首席法务官兼秘书，2008年至2014年担任Vice President、总法律顾问兼秘书。Gilbert女士目前在Arcutis Biotherapeutics（一家医学皮肤病学公司）和CytomX Therapeutics（一家生命科学公司）的董事会任职。从2019年11月至2020年2月，吉尔伯特女士担任医学皮肤科公司Dermira，Inc.的董事会成员。2017年1月至2019年4月，吉尔伯特女士担任生物制药公司Achaogen，Inc.的董事会成员。Gilbert女士拥有Tufts University的学士学位和Northwestern University School of Law的法学博士学位。
Halley Gilbert,has served as Cargo Therapeutics, Inc. Chief Legal Officer since since August 2023. Prior to joining Cargo Therapeutics, Inc. company, from August 2021 to May 2022, Ms. Gilbert served as Chief Legal Officer for NeoGenomics Laboratories, Inc., a global cancer genomics and informatics company. Prior to NeoGenomics, from June 2020 to August 2021, Ms. Gilbert was Chief Operating Officer for Invivyd, Inc. (formerly Adagio Therapeutics, Inc.), a biopharmaceutical company. Prior to Invivyd, from February 2008 to February 2020, Ms. Gilbert worked at Ironwood Pharmaceuticals, Inc., a gastrointestinal healthcare company, in roles of increasing responsibility, including Chief Administrative Officer & SVP of Corporate Development, and Chief Legal Officer. Ms. Gilbert currently serves on the board of directors of CytomX Therapeutics, Inc., Vaxcyte, Inc. and Arcutis Biotherapeutics, Inc. Ms. Gilbert earned a J.D. from Northwestern University Pritzker School of Law and a B.A. from Tufts University. - Halley Gilbert自2020年4月以来一直担任我们的董事会成员。2008年至2020年2月，吉尔伯特女士曾在生物制药公司IronwoodPharmaceuticals，Inc.担任多个职位，包括2019年3月至2020年2月担任高级副总裁，企业发展和首席行政官，担任高级副总裁，2014年至2019年3月担任首席法务官兼秘书，2008年至2014年担任Vice President、总法律顾问兼秘书。Gilbert女士目前在Arcutis Biotherapeutics（一家医学皮肤病学公司）和CytomX Therapeutics（一家生命科学公司）的董事会任职。从2019年11月至2020年2月，吉尔伯特女士担任医学皮肤科公司Dermira，Inc.的董事会成员。2017年1月至2019年4月，吉尔伯特女士担任生物制药公司Achaogen，Inc.的董事会成员。Gilbert女士拥有Tufts University的学士学位和Northwestern University School of Law的法学博士学位。
- Halley Gilbert,has served as Cargo Therapeutics, Inc. Chief Legal Officer since since August 2023. Prior to joining Cargo Therapeutics, Inc. company, from August 2021 to May 2022, Ms. Gilbert served as Chief Legal Officer for NeoGenomics Laboratories, Inc., a global cancer genomics and informatics company. Prior to NeoGenomics, from June 2020 to August 2021, Ms. Gilbert was Chief Operating Officer for Invivyd, Inc. (formerly Adagio Therapeutics, Inc.), a biopharmaceutical company. Prior to Invivyd, from February 2008 to February 2020, Ms. Gilbert worked at Ironwood Pharmaceuticals, Inc., a gastrointestinal healthcare company, in roles of increasing responsibility, including Chief Administrative Officer & SVP of Corporate Development, and Chief Legal Officer. Ms. Gilbert currently serves on the board of directors of CytomX Therapeutics, Inc., Vaxcyte, Inc. and Arcutis Biotherapeutics, Inc. Ms. Gilbert earned a J.D. from Northwestern University Pritzker School of Law and a B.A. from Tufts University.
- Peter Hirth
-
暂无中文简介
Peter Hirth has served on our board of directors since September 2016. In 2001 Dr. Hirth founded Plexxikon, Inc., a pharmaceutical company, and served as its Chief Executive Officer until April 2013. Dr. Hirth currently serves on the boards of directors of several private life sciences companies. Dr. Hirth holds a Ph.D. in Molecular Genetics from Heidelberg University, Germany. -
暂无中文简介
- Peter Hirth has served on our board of directors since September 2016. In 2001 Dr. Hirth founded Plexxikon, Inc., a pharmaceutical company, and served as its Chief Executive Officer until April 2013. Dr. Hirth currently serves on the boards of directors of several private life sciences companies. Dr. Hirth holds a Ph.D. in Molecular Genetics from Heidelberg University, Germany.
- Rob Hopfner
-
Rob Hopfner自2017年12月以来一直担任我们的董事会成员。自2017年10月以来，Hopfner博士一直担任风险投资公司Pivotal BioVenture Partners的管理合伙人。Hopfner博士还于2007年6月至2009年10月担任风险投资公司Bay City Capital的负责人，并于2009年10月至2017年9月担任董事总经理兼合伙人。Hopfner博士目前任职于私人生命科学公司的董事会。Hopfner博士拥有工商管理硕士学位。Saskatchewan大学药剂学博士学位和Chicago大学工商管理硕士学位。
Rob Hopfner has served on our board of directors since December 2017. Since October 2017 Dr. Hopfner has served as a Managing Partner at Pivotal bioVenture Partners, a venture capital firm. Dr. Hopfner also served as a Principal at Bay City Capital, a venture capital firm, from June 2007 to October 2009 and as a Managing Director and Partner from October 2009 to September 2017. Dr. Hopfner currently serves on the boards of directors of private life sciences companies. Dr. Hopfner holds a B.Sc. in Pharmacy and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago. - Rob Hopfner自2017年12月以来一直担任我们的董事会成员。自2017年10月以来，Hopfner博士一直担任风险投资公司Pivotal BioVenture Partners的管理合伙人。Hopfner博士还于2007年6月至2009年10月担任风险投资公司Bay City Capital的负责人，并于2009年10月至2017年9月担任董事总经理兼合伙人。Hopfner博士目前任职于私人生命科学公司的董事会。Hopfner博士拥有工商管理硕士学位。Saskatchewan大学药剂学博士学位和Chicago大学工商管理硕士学位。
- Rob Hopfner has served on our board of directors since December 2017. Since October 2017 Dr. Hopfner has served as a Managing Partner at Pivotal bioVenture Partners, a venture capital firm. Dr. Hopfner also served as a Principal at Bay City Capital, a venture capital firm, from June 2007 to October 2009 and as a Managing Director and Partner from October 2009 to September 2017. Dr. Hopfner currently serves on the boards of directors of private life sciences companies. Dr. Hopfner holds a B.Sc. in Pharmacy and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago.
- Peter Hirth
-
Peter Hirth于2019年7月起担任Trex Bio，Inc.董事会成员。Hirth博士在生物技术和药物发现与开发方面拥有超过30年的经验。在进入生物技术领域之前，Hirth博士曾担任德国勃林格曼海姆公司的研究副总裁。从1991年到2000年，他在Sugen，Inc.担任过多个职位，最终担任总裁，在那里他从一开始就帮助建立公司，并通过肿瘤学的临床试验推进激酶抑制剂。Sugen于1999年被Pharmacia/辉瑞收购。2001年，Hirth博士创立了制药公司PlexXikon，Inc.，并担任首席执行官至2013年4月。PlexXikon于2011年被Daiichi Sankyo收购。Hirth博士目前在Aligos Therapeutics、IO Biotech，Inc.以及多家私营公司的董事会任职。此前曾于2017年1月至2025年4月担任Vaxcyte，公司董事会成员。Hirth博士拥有德国海德堡大学分子遗传学理学硕士和博士学位，并在加州大学圣地亚哥分校完成博士后工作。
Peter Hirth has served as a member of Trex Bio, Inc.'s board of directors since July 2019. Dr. Hirth has over 30 years of experience in biotechnology and pharmaceutical discovery and development. Prior to entering the biotechnology sector, Dr. Hirth served as vice president of Research at Boehringer Mannheim in Germany. From 1991 to 2000, he held several positions at Sugen, Inc., ultimately serving as President, where he helped build the company from inception and advance kinase inhibitors through clinical trials in oncology. Sugen was acquired by Pharmacia/Pfizer in 1999. In 2001, Dr. Hirth co founded Plexxikon, Inc., a pharmaceutical company, and served as its chief executive officer until April 2013. Plexxikon was acquired by Daiichi Sankyo in 2011. Dr. Hirth currently serves on the board of directors of Aligos Therapeutics, IO Biotech, Inc., and several private companies. He previously served on the board of directors of Vaxcyte, Inc. from January 2017 to April 2025. Dr. Hirth holds an MSc and PhD in Molecular Genetics from Heidelberg University, Germany and completed his post doctoral work at the University of California, San Diego. - Peter Hirth于2019年7月起担任Trex Bio，Inc.董事会成员。Hirth博士在生物技术和药物发现与开发方面拥有超过30年的经验。在进入生物技术领域之前，Hirth博士曾担任德国勃林格曼海姆公司的研究副总裁。从1991年到2000年，他在Sugen，Inc.担任过多个职位，最终担任总裁，在那里他从一开始就帮助建立公司，并通过肿瘤学的临床试验推进激酶抑制剂。Sugen于1999年被Pharmacia/辉瑞收购。2001年，Hirth博士创立了制药公司PlexXikon，Inc.，并担任首席执行官至2013年4月。PlexXikon于2011年被Daiichi Sankyo收购。Hirth博士目前在Aligos Therapeutics、IO Biotech，Inc.以及多家私营公司的董事会任职。此前曾于2017年1月至2025年4月担任Vaxcyte，公司董事会成员。Hirth博士拥有德国海德堡大学分子遗传学理学硕士和博士学位，并在加州大学圣地亚哥分校完成博士后工作。
- Peter Hirth has served as a member of Trex Bio, Inc.'s board of directors since July 2019. Dr. Hirth has over 30 years of experience in biotechnology and pharmaceutical discovery and development. Prior to entering the biotechnology sector, Dr. Hirth served as vice president of Research at Boehringer Mannheim in Germany. From 1991 to 2000, he held several positions at Sugen, Inc., ultimately serving as President, where he helped build the company from inception and advance kinase inhibitors through clinical trials in oncology. Sugen was acquired by Pharmacia/Pfizer in 1999. In 2001, Dr. Hirth co founded Plexxikon, Inc., a pharmaceutical company, and served as its chief executive officer until April 2013. Plexxikon was acquired by Daiichi Sankyo in 2011. Dr. Hirth currently serves on the board of directors of Aligos Therapeutics, IO Biotech, Inc., and several private companies. He previously served on the board of directors of Vaxcyte, Inc. from January 2017 to April 2025. Dr. Hirth holds an MSc and PhD in Molecular Genetics from Heidelberg University, Germany and completed his post doctoral work at the University of California, San Diego.
- Moncef Slaoui
-
Moncef Slaoui于2006年5月17日接受任命。Moncef于1988年加入葛兰素史克生物制剂（GSK Biologicals），他在该公司操作强壮疫苗流水线，后来在领导研发部前，他领导了全球制药业务发展部。Moncef 于2010年全面负责领导葛兰素史克（GSK）的肿瘤业务，于2011年全面负责领导葛兰素史克疫苗部。他在布鲁塞尔自由大学（Université Libre de Bruxelles）获得分子生物学与免疫学的博士学位。
Moncef Slaoui has served as a member of board of directors of Moderna, Inc. since July 2017.Dr. Slaoui joined GlaxoSmithKline Plc NYSE: GSK ("GSK") in 1988 where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006.He assumed overall responsibility for GSK's Oncology Business in 2010 for GSK Vaccines in 2011 and for all Global Franchises in 2012. Dr. Slaoui is Chairman of the board of directors of Galvani Bioelectronics, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences. Dr. Slaoui has advised the U.S. President's Council of Advisors on Science and Technology, was a member of the Board of the Agency for Science, Technology, & Research until January 2011 the PhRMA Foundation Board from 2008 to 2016 and the Advisory Committee to the Director of the National Institutes of Health from 2011 to 2016. Dr. Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA). Dr. Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr. Slaoui received a Ph.D. in Molecular Biology and Immunology from Universite Libre de Bruxelles. - Moncef Slaoui于2006年5月17日接受任命。Moncef于1988年加入葛兰素史克生物制剂（GSK Biologicals），他在该公司操作强壮疫苗流水线，后来在领导研发部前，他领导了全球制药业务发展部。Moncef 于2010年全面负责领导葛兰素史克（GSK）的肿瘤业务，于2011年全面负责领导葛兰素史克疫苗部。他在布鲁塞尔自由大学（Université Libre de Bruxelles）获得分子生物学与免疫学的博士学位。
- Moncef Slaoui has served as a member of board of directors of Moderna, Inc. since July 2017.Dr. Slaoui joined GlaxoSmithKline Plc NYSE: GSK ("GSK") in 1988 where he engineered the development of a robust vaccines pipeline. He then led worldwide business development for pharmaceutical products before his appointment to lead research and development in 2006.He assumed overall responsibility for GSK's Oncology Business in 2010 for GSK Vaccines in 2011 and for all Global Franchises in 2012. Dr. Slaoui is Chairman of the board of directors of Galvani Bioelectronics, a company launched in November 2016 that GSK jointly owns with Verily Life Sciences. Dr. Slaoui has advised the U.S. President's Council of Advisors on Science and Technology, was a member of the Board of the Agency for Science, Technology, & Research until January 2011 the PhRMA Foundation Board from 2008 to 2016 and the Advisory Committee to the Director of the National Institutes of Health from 2011 to 2016. Dr. Slaoui previously served on the board of directors of Intellia Therapeutics Inc. (Nasdaq: NTLA). Dr. Slaoui is also a former Professor of Immunology at the University of Mons, Belgium. Dr. Slaoui received a Ph.D. in Molecular Biology and Immunology from Universite Libre de Bruxelles.
- Robert Hopfner
-
Robert Hopfner， 哲学博士。2010年12月起，他担任我公司董事会成员。2002年8月起，他担任风险资本公司Bay City Capital的投资合伙人。加入 Bay City Capital之前，他担任DuPont Pharmaceuticals商业发展与战略规划部门助理和加拿大西部种子生物技术风险投资公司Ag-West Biotech的分析师。他是一家私人公司的董事会成员。他在萨省大学（University of Saskatchewan）获得药理学博士学位和药学学士学位，在芝加哥大学布斯商学院（University of Chicago Booth School of Business）获得企业、财政与战略工商管理硕士学位。
Robert Hopfner has served as a member of Rallybio's Board since March 2020. Since October 2017, Dr. Hopfner has served as a Managing Partner at Pivotal bioVenture Partners LLC, a venture capital firm. Prior to Pivotal, Dr. Hopfner served as a Principal at Bay City Capital LLC, a venture capital firm, from June 2007 to October 2009 and as a Managing Director and Partner from October 2009 to September 2017. Dr. Hopfner currently serves as a board member of Evommune, Inc., and on the boards of directors of a number of private life sciences companies. Dr. Hopfner previously served on the board of directors of Vaxcyte, Inc., Oculis Holding AG and Inozyme Pharma Inc. Dr. Hopfner received a B.Sc. in Pharmacy and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago. - Robert Hopfner， 哲学博士。2010年12月起，他担任我公司董事会成员。2002年8月起，他担任风险资本公司Bay City Capital的投资合伙人。加入 Bay City Capital之前，他担任DuPont Pharmaceuticals商业发展与战略规划部门助理和加拿大西部种子生物技术风险投资公司Ag-West Biotech的分析师。他是一家私人公司的董事会成员。他在萨省大学（University of Saskatchewan）获得药理学博士学位和药学学士学位，在芝加哥大学布斯商学院（University of Chicago Booth School of Business）获得企业、财政与战略工商管理硕士学位。
- Robert Hopfner has served as a member of Rallybio's Board since March 2020. Since October 2017, Dr. Hopfner has served as a Managing Partner at Pivotal bioVenture Partners LLC, a venture capital firm. Prior to Pivotal, Dr. Hopfner served as a Principal at Bay City Capital LLC, a venture capital firm, from June 2007 to October 2009 and as a Managing Director and Partner from October 2009 to September 2017. Dr. Hopfner currently serves as a board member of Evommune, Inc., and on the boards of directors of a number of private life sciences companies. Dr. Hopfner previously served on the board of directors of Vaxcyte, Inc., Oculis Holding AG and Inozyme Pharma Inc. Dr. Hopfner received a B.Sc. in Pharmacy and a Ph.D. in Pharmacology from the University of Saskatchewan and an M.B.A. from the University of Chicago.
- Heath Lukatch
-
Heath Lukatch，他一直担任Bicara Therapeutics公司的董事会成员（2013年8月以来）。自2020年3月以来，Lukatch博士一直担任Red Tree Venture Capital（私人持有的生命科学风险投资公司）的创始人和管理合伙人。在创立Red Tree Venture Capital之前，从2015年5月到2020年3月，Lukatch博士在TPG工作，担任TPG的Biotech、Growth和RISE平台的合伙人、董事总经理和生命科学投资团队负责人。2006年4月，Lukatch博士共同创立了Novo Ventures （US） Inc.的旧金山办事处，这是一家风险投资公司，他在那里担任合伙人至2015年4月。Lukatch博士目前是生物技术公司Vaxcyte, Inc.（纳斯达克股票代码：PCVX）的董事会成员，自2018年5月以来，他还担任多家私营公司的董事会成员。此前，Lukatch博士于2021年1月至2023年11月担任生物技术公司Cargo Therapeutics, Inc.（纳斯达克股票代码：CRGX）的董事会成员，2016年12月至2023年6月担任制药公司Satsuma Pharmaceuticals, Inc.（纳斯达克股票代码：STSA）的董事会成员，2006年12月至2022年3月担任医疗技术公司Inogen, Inc.（纳斯达克股票代码：INGN）的董事会成员，以及Flexion Therapeutics, Inc.(纳斯达克股票代码：从2012年12月到2021年11月，该公司被Pacira BioSciences, Inc.和其他几家私人公司收购。Lukatch博士在斯坦福大学获得神经科学博士学位，在加州大学伯克利分校获得生物化学学士学位。
Heath Lukatch,has served as a member of Bicara Therapeutics Inc. board of directors since August 2023. Since March 2020, Dr. Lukatch has served as Founder and Managing Partner of Red Tree Venture Capital, a privately held life sciences venture capital firm. Prior to founding Red Tree Venture Capital, from May 2015 to March 2020, Dr. Lukatch worked at TPG, where he was Partner, Managing Director and Life Sciences Investment Team Leader in TPG's Biotech, Growth and RISE platforms. In April 2006, Dr. Lukatch co-founded Novo Ventures (US) Inc.'s San Francisco office, a venture capital firm, where he was a Partner through April 2015. Dr. Lukatch is currently a member of the board of directors Vaxcyte, Inc. (NASDAQ: PCVX), a biotechnology company, since May 2018 and also serves on the boards of directors of various private companies. Previously, Dr. Lukatch served on the board of Cargo Therapeutics, Inc. (NASDAQ: CRGX), a biotechnology company, from January 2021 to November 2023, Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA), a pharmaceutical company, from December 2016 to June 2023, Inogen, Inc. (NASDAQ: INGN), a medical technology company, from December 2006 to March 2022, and Flexion Therapeutics, Inc. (NASDAQ: FLXN), a biopharmaceutical company from December 2012 to November 2021, when it was acquired by Pacira BioSciences, Inc., and several other private companies. Dr. Lukatch received his Ph.D. in Neuroscience from Stanford University and his B.A. in Biochemistry from the University of California at Berkeley. - Heath Lukatch，他一直担任Bicara Therapeutics公司的董事会成员（2013年8月以来）。自2020年3月以来，Lukatch博士一直担任Red Tree Venture Capital（私人持有的生命科学风险投资公司）的创始人和管理合伙人。在创立Red Tree Venture Capital之前，从2015年5月到2020年3月，Lukatch博士在TPG工作，担任TPG的Biotech、Growth和RISE平台的合伙人、董事总经理和生命科学投资团队负责人。2006年4月，Lukatch博士共同创立了Novo Ventures （US） Inc.的旧金山办事处，这是一家风险投资公司，他在那里担任合伙人至2015年4月。Lukatch博士目前是生物技术公司Vaxcyte, Inc.（纳斯达克股票代码：PCVX）的董事会成员，自2018年5月以来，他还担任多家私营公司的董事会成员。此前，Lukatch博士于2021年1月至2023年11月担任生物技术公司Cargo Therapeutics, Inc.（纳斯达克股票代码：CRGX）的董事会成员，2016年12月至2023年6月担任制药公司Satsuma Pharmaceuticals, Inc.（纳斯达克股票代码：STSA）的董事会成员，2006年12月至2022年3月担任医疗技术公司Inogen, Inc.（纳斯达克股票代码：INGN）的董事会成员，以及Flexion Therapeutics, Inc.(纳斯达克股票代码：从2012年12月到2021年11月，该公司被Pacira BioSciences, Inc.和其他几家私人公司收购。Lukatch博士在斯坦福大学获得神经科学博士学位，在加州大学伯克利分校获得生物化学学士学位。
- Heath Lukatch,has served as a member of Bicara Therapeutics Inc. board of directors since August 2023. Since March 2020, Dr. Lukatch has served as Founder and Managing Partner of Red Tree Venture Capital, a privately held life sciences venture capital firm. Prior to founding Red Tree Venture Capital, from May 2015 to March 2020, Dr. Lukatch worked at TPG, where he was Partner, Managing Director and Life Sciences Investment Team Leader in TPG's Biotech, Growth and RISE platforms. In April 2006, Dr. Lukatch co-founded Novo Ventures (US) Inc.'s San Francisco office, a venture capital firm, where he was a Partner through April 2015. Dr. Lukatch is currently a member of the board of directors Vaxcyte, Inc. (NASDAQ: PCVX), a biotechnology company, since May 2018 and also serves on the boards of directors of various private companies. Previously, Dr. Lukatch served on the board of Cargo Therapeutics, Inc. (NASDAQ: CRGX), a biotechnology company, from January 2021 to November 2023, Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA), a pharmaceutical company, from December 2016 to June 2023, Inogen, Inc. (NASDAQ: INGN), a medical technology company, from December 2006 to March 2022, and Flexion Therapeutics, Inc. (NASDAQ: FLXN), a biopharmaceutical company from December 2012 to November 2021, when it was acquired by Pacira BioSciences, Inc., and several other private companies. Dr. Lukatch received his Ph.D. in Neuroscience from Stanford University and his B.A. in Biochemistry from the University of California at Berkeley.
- Kurt von Emster
-
Kurt von Emster，目前担任风险投资公司Abingworth LLP的管理合伙人，自2015年1月起担任该公司的合伙人。von Emster先生自2020年12月起担任生物技术公司Tizona Therapeutics，Inc.的董事会成员，自2020年12月起担任免疫治疗公司Trishula Therapeutics，Inc.，自2020年12月起担任制药公司Orbus Therapeutics，Inc.，自2020年7月起担任专业制药公司SFJ Pharmaceuticals，Inc.，自2020年4月起担任生物技术公司Jasper Therapeutics, Inc.，自2019年11月起担任生物制药疫苗公司VaxcyteVaxcyte，自2015年7月起担任生物技术公司CymaBay Therapeutics，Inc.，自2009年4月起担任。von Emster先生此前曾在以下公司的董事会任职：CRISPR Therapeutics，Inc.于2015年3月至2019年6月Kesios Therapeutics Ltd.于2015年11月至2017年1月Cytos Biotechnology AG于2012年11月至2016年1月（于2016年1月合并并更名为Kuros Biosciences AG），Somaxon制药 Inc.于2014年2月至2015年3月Facet Biotechnology Corporation（于2010年4月被雅培收购）于2009年2月至2010年4月以及TERM3（于2013年3月被Pernix疗法控股，Inc.收购）于2005年8月至2013年3月。此外，von Emster先生于2009年与他人共同创立了专注于医疗保健的投资公司venBio LLC，并担任合伙人至2014年。在此之前，von Emster先生于2000年至2009年担任生物技术私募股权公司MPM Capital，Inc.的普通合伙人。von Emster先生还曾于1989年至2000年在富兰克林邓普顿集团担任生物技术和医疗保健分析师和投资组合经理。von Emster先生在加州大学圣巴巴拉分校获得商业和经济学学士学位，是一名特许金融分析师（C.F.A。）。
Kurt von Emster has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2023. He joined Abingworth LLP, a venture capital firm, as a Partner in January 2015 and has served as a Managing Partner since July 2015. Abingworth LLP was acquired by The Carlyle Group in 2022 and is a wholly owned subsidiary of The Carlyle Group. From May 2009 until January 2015, he served as a Partner at venBio LLC, a venture capital firm he co founded. He currently serves on the boards of directors of Jasper Therapeutics, Inc., a biotechnology company, and several privately held companies. He previously served on the boards of directors of CymaBay Therapeutics, Inc. until April 2024, CRISPR Therapeutics AG until June 2019, Vaxcyte, Inc. until June 2022, and Vera Therapeutics, Inc. until May 2022. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (CFA). - Kurt von Emster，目前担任风险投资公司Abingworth LLP的管理合伙人，自2015年1月起担任该公司的合伙人。von Emster先生自2020年12月起担任生物技术公司Tizona Therapeutics，Inc.的董事会成员，自2020年12月起担任免疫治疗公司Trishula Therapeutics，Inc.，自2020年12月起担任制药公司Orbus Therapeutics，Inc.，自2020年7月起担任专业制药公司SFJ Pharmaceuticals，Inc.，自2020年4月起担任生物技术公司Jasper Therapeutics, Inc.，自2019年11月起担任生物制药疫苗公司VaxcyteVaxcyte，自2015年7月起担任生物技术公司CymaBay Therapeutics，Inc.，自2009年4月起担任。von Emster先生此前曾在以下公司的董事会任职：CRISPR Therapeutics，Inc.于2015年3月至2019年6月Kesios Therapeutics Ltd.于2015年11月至2017年1月Cytos Biotechnology AG于2012年11月至2016年1月（于2016年1月合并并更名为Kuros Biosciences AG），Somaxon制药 Inc.于2014年2月至2015年3月Facet Biotechnology Corporation（于2010年4月被雅培收购）于2009年2月至2010年4月以及TERM3（于2013年3月被Pernix疗法控股，Inc.收购）于2005年8月至2013年3月。此外，von Emster先生于2009年与他人共同创立了专注于医疗保健的投资公司venBio LLC，并担任合伙人至2014年。在此之前，von Emster先生于2000年至2009年担任生物技术私募股权公司MPM Capital，Inc.的普通合伙人。von Emster先生还曾于1989年至2000年在富兰克林邓普顿集团担任生物技术和医疗保健分析师和投资组合经理。von Emster先生在加州大学圣巴巴拉分校获得商业和经济学学士学位，是一名特许金融分析师（C.F.A。）。
- Kurt von Emster has served as a member of Iambic Therapeutics, Inc.'s board of directors since September 2023. He joined Abingworth LLP, a venture capital firm, as a Partner in January 2015 and has served as a Managing Partner since July 2015. Abingworth LLP was acquired by The Carlyle Group in 2022 and is a wholly owned subsidiary of The Carlyle Group. From May 2009 until January 2015, he served as a Partner at venBio LLC, a venture capital firm he co founded. He currently serves on the boards of directors of Jasper Therapeutics, Inc., a biotechnology company, and several privately held companies. He previously served on the boards of directors of CymaBay Therapeutics, Inc. until April 2024, CRISPR Therapeutics AG until June 2019, Vaxcyte, Inc. until June 2022, and Vera Therapeutics, Inc. until May 2022. Mr. von Emster holds a B.S. in Business and Economics from the University of California, Santa Barbara and is a Chartered Financial Analyst (CFA).
- Patrick Heron
-
Patrick Heron自2017年3月以来一直担任我们的董事会成员。自1999年8月以来，Heron先生一直担任Frazier梦百合Partners（一家风险投资公司）的管理普通合伙人。Heron先生目前在制药公司Iterum Therapeutics Plc、制药公司MirumPharmaceuticals，Inc.和医学皮肤科公司Arcutis Biotherapeutics的董事会任职，并在几家私营生命科学公司的董事会任职。Heron先生拥有北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）的政治学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Patrick Heron,has served on board of directors since July 2020. He has been a Managing Partner of Frazier's Life Sciences team since August 1999. Prior to that, Mr. Heron helped develop McKinsey & Company's west coast biotechnology consulting practice. He currently serves on the boards of directors of HilleVax, Inc. (Nasdaq: HLVX) since September 2021 and Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) since November 2018, as well as chairman of the board of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) since January 2017. Mr. Heron previously served as chairman of the board of Scout Bio, Inc. from January 2018 to December 2023, and as a director of SanReno Therapeutics from January 2022 to December 2023, Imago Biosciences, Inc. (acquired by Merck & Co., Inc). from October 2014 to May 2022, Vaxcyte, Inc. (Nasdaq: PCVX) from April 2017 to September 2021, Passage Bio, Inc. (Nasdaq: PASG) from July 2018 to June 2021 and Iterum Therapeutics plc (Nasdaq: ITRM) from August 2015 to April 2021. He has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage drug discovery companies to $100M commercial-stage dermatology companies. He received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar. - Patrick Heron自2017年3月以来一直担任我们的董事会成员。自1999年8月以来，Heron先生一直担任Frazier梦百合Partners（一家风险投资公司）的管理普通合伙人。Heron先生目前在制药公司Iterum Therapeutics Plc、制药公司MirumPharmaceuticals，Inc.和医学皮肤科公司Arcutis Biotherapeutics的董事会任职，并在几家私营生命科学公司的董事会任职。Heron先生拥有北卡罗莱纳大学教堂山分校（University of North Carolina at Chapel Hill）的政治学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Patrick Heron,has served on board of directors since July 2020. He has been a Managing Partner of Frazier's Life Sciences team since August 1999. Prior to that, Mr. Heron helped develop McKinsey & Company's west coast biotechnology consulting practice. He currently serves on the boards of directors of HilleVax, Inc. (Nasdaq: HLVX) since September 2021 and Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) since November 2018, as well as chairman of the board of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) since January 2017. Mr. Heron previously served as chairman of the board of Scout Bio, Inc. from January 2018 to December 2023, and as a director of SanReno Therapeutics from January 2022 to December 2023, Imago Biosciences, Inc. (acquired by Merck & Co., Inc). from October 2014 to May 2022, Vaxcyte, Inc. (Nasdaq: PCVX) from April 2017 to September 2021, Passage Bio, Inc. (Nasdaq: PASG) from July 2018 to June 2021 and Iterum Therapeutics plc (Nasdaq: ITRM) from August 2015 to April 2021. He has successfully partnered with entrepreneurs across a range of company types and stages, from early-stage drug discovery companies to $100M commercial-stage dermatology companies. He received his M.B.A. from Harvard Business School. He also holds a B.A. from the University of North Carolina at Chapel Hill, where he is a Phi Beta Kappa graduate and Morehead Scholar.
高管简历
中英对照 | 中文 | 英文- Jane Wright Mitchell
Jane Wright Mitchell，2014年7月起，担任本公司的首席法律官。2012年1月至2014年6月，她是生物制药公司Mesoblast, Inc的副法律总顾问。加入Mesoblast之前，2010年11月至2012年1月，她担任Purdue Pharma的副法律总顾问；2008年5月至2010年10月，担任 NeurogesX, Inc.的副法律总顾问。她在Chicago-Kent College of Law获得法律博士学位，在University of Illinois, Chicago获得药物博士学位，在Clemson University获得生物科学学士学位。她是伊利诺斯州的注册药剂师，有资格在U.S. Patent and Trademark Office开展业务。
Jane Wright Mitchell has served as our General Counsel since January 2019. From November 2017 to December 2018 Ms. Wright-Mitchell served as Chief Legal Officer at Steep Hill, Inc., a cannabis testing and analytics company. From July 2014 to November 2017 Ms. Wright-Mitchell served as Chief Legal Officer at AcelRx Pharmaceuticals, Inc., a pharmaceutical company. Ms. Wright-Mitchell holds a B.S. in Biological Sciences from Clemson University, a PharmD from the University of Illinois at Chicago and a J.D. from Chicago-Kent College of Law, Illinois Institute of Technology.- Jane Wright Mitchell，2014年7月起，担任本公司的首席法律官。2012年1月至2014年6月，她是生物制药公司Mesoblast, Inc的副法律总顾问。加入Mesoblast之前，2010年11月至2012年1月，她担任Purdue Pharma的副法律总顾问；2008年5月至2010年10月，担任 NeurogesX, Inc.的副法律总顾问。她在Chicago-Kent College of Law获得法律博士学位，在University of Illinois, Chicago获得药物博士学位，在Clemson University获得生物科学学士学位。她是伊利诺斯州的注册药剂师，有资格在U.S. Patent and Trademark Office开展业务。
- Jane Wright Mitchell has served as our General Counsel since January 2019. From November 2017 to December 2018 Ms. Wright-Mitchell served as Chief Legal Officer at Steep Hill, Inc., a cannabis testing and analytics company. From July 2014 to November 2017 Ms. Wright-Mitchell served as Chief Legal Officer at AcelRx Pharmaceuticals, Inc., a pharmaceutical company. Ms. Wright-Mitchell holds a B.S. in Biological Sciences from Clemson University, a PharmD from the University of Illinois at Chicago and a J.D. from Chicago-Kent College of Law, Illinois Institute of Technology.
- Grant E. Pickering
GrantE.Pickering是我们的联合创始人，自2013年11月以来担任我们的总裁兼首席执行官，并担任我们的董事会成员。2013年5月至2015年4月，皮克林先生担任生物技术公司Atreca，Inc.的战略顾问。加入Vaxcyte公司之前，他曾担任Mymetics Corporation（传染病病毒体疫苗开发商）的首席执行官。在此之前，皮克林先生是风险投资公司凯鹏华盈（Kleiner Perkins）的常驻高管，也是生物制药公司Dendreon Corporation（McKinsey）的运营高级副总裁。Pickering自2008年3月起担任Juvaris Biotherapeutics，Inc.（一家生物制药公司）首席执行官。Pickering先生拥有Penn State University的市场营销学士学位和Georgetown University的工商管理硕士学位。
Grant E. Pickering is our co-founder and has served as our President and Chief Executive Officer and as a member of our board of directors since November 2013. From May 2013 to April 2015 Mr. Pickering served as Strategic Advisor at Atreca, Inc., a biotechnology company. Prior to joining Vaxcyte, he was Chief Executive Officer of Mymetics Corporation, a developer of virosomal vaccines for infectious diseases. Prior to that, Mr. Pickering was an Executive-in-Residence at Kleiner Perkins, a venture capital firm, and Senior Vice President of Operations of Dendreon Corporation, a biopharmaceutical company. Since March 2008 Mr. Pickering has served as Chief Executive Officer of Juvaris BioTherapeutics, Inc., a biopharmaceutical company. Mr. Pickering holds a B.S. in Marketing from Penn State University and an M.B.A. from Georgetown University.- GrantE.Pickering是我们的联合创始人，自2013年11月以来担任我们的总裁兼首席执行官，并担任我们的董事会成员。2013年5月至2015年4月，皮克林先生担任生物技术公司Atreca，Inc.的战略顾问。加入Vaxcyte公司之前，他曾担任Mymetics Corporation（传染病病毒体疫苗开发商）的首席执行官。在此之前，皮克林先生是风险投资公司凯鹏华盈（Kleiner Perkins）的常驻高管，也是生物制药公司Dendreon Corporation（McKinsey）的运营高级副总裁。Pickering自2008年3月起担任Juvaris Biotherapeutics，Inc.（一家生物制药公司）首席执行官。Pickering先生拥有Penn State University的市场营销学士学位和Georgetown University的工商管理硕士学位。
- Grant E. Pickering is our co-founder and has served as our President and Chief Executive Officer and as a member of our board of directors since November 2013. From May 2013 to April 2015 Mr. Pickering served as Strategic Advisor at Atreca, Inc., a biotechnology company. Prior to joining Vaxcyte, he was Chief Executive Officer of Mymetics Corporation, a developer of virosomal vaccines for infectious diseases. Prior to that, Mr. Pickering was an Executive-in-Residence at Kleiner Perkins, a venture capital firm, and Senior Vice President of Operations of Dendreon Corporation, a biopharmaceutical company. Since March 2008 Mr. Pickering has served as Chief Executive Officer of Juvaris BioTherapeutics, Inc., a biopharmaceutical company. Mr. Pickering holds a B.S. in Marketing from Penn State University and an M.B.A. from Georgetown University.
- Andrew Guggenhime
Andrew Guggenhime自2018年7月以来一直担任我们的董事会成员。Guggenhime先生目前担任Vaxcyte，Inc.公司（一家公共疫苗公司）的首席财务官和首席商务官。2014年4月至2020年5月，Guggenhime先生担任Dermira的首席财务官，2014年4月至2018年5月，他还担任首席运营官。2011年9月至2014年4月，Guggenhime先生担任分子诊断生命科学公司Cardiodx，Inc.的首席财务官，并于2014年4月至2016年7月担任Cardiodx董事会成员。Guggenhime从2010年9月到2011年4月担任Calistoga Pharmaceuticals，Inc.（一家生物技术公司，2011年4月被吉利德科学公司收购）首席财务官。Guggenhime从2008年12月到2010年6月担任Facet Biotech Corporation（一家生物技术公司，2010年4月被雅培公司收购）高级副总裁和首席财务官。Facet Biotech Corporation从PDLBioPharma，Inc.分拆出来，2006年4月至2008年12月，Guggenhime先生在该公司担任高级副总裁和首席财务官。2000年10月至2006年3月，Guggenhime先生担任Neoforma，Inc.的首席财务官，该公司是一家为梦百合行业提供供应链管理解决方案的供应商，于2006年3月被Global梦百合Exchange，LLC收购。2000年1月至10月，Guggenhime先生担任Neoforma’；s公司发展部的Vice President。Guggenhime先生的职业生涯始于美林公司（Merrill Lynch&Co.）和富国银行集团公司（Citigroup）的金融服务。Guggenhime先生拥有Middlebury College的国际政治和经济学学士学位，并持有西北大学J.L.Kellogg管理研究生院的工商管理硕士学位。
Andrew Guggenhime has served on our board of directors since April 2021. Mr. Guggenhime currently serves as the President and Chief Financial Officer at Vaxcyte, Inc., positions he has held since December and May 2020 respectively. Prior to joining Vaxcyte, he served as Chief Financial Officer of Dermira, Inc. from April 2014 through the acquisition of the company by Eli Lilly and Company in February 2020. Prior to Dermira, Mr. Guggenhime served as Chief Financial Officer for CardioDx, Inc. from September 2011 to April 2014 and as a director of the company from April 2014 to July 2016. He also served as Chief Financial Officer for Calistoga Pharmaceuticals, Inc., from September 2010 to April 2011 which was acquired by Gilead Sciences, Inc. in 2011 and as Chief Financial Officer for Facet Biotech Corporation, from December 2008 to June 2010 which was acquired by Abbott Laboratories in April 2010. Mr. Guggenhime previously served as Chief Financial Officer of PDL BioPharma, Inc., until Facet Biotech was spun off from PDL BioPharma in December 2008. Prior to joining Facet Biotech, he served as Chief Financial Officer for Neoforma, Inc., which was acquired by Global Healthcare Exchange, LLC in March 2006. Mr. Guggenhime began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He received his B.A. in international politics and economics from Middlebury College and his M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.- Andrew Guggenhime自2018年7月以来一直担任我们的董事会成员。Guggenhime先生目前担任Vaxcyte，Inc.公司（一家公共疫苗公司）的首席财务官和首席商务官。2014年4月至2020年5月，Guggenhime先生担任Dermira的首席财务官，2014年4月至2018年5月，他还担任首席运营官。2011年9月至2014年4月，Guggenhime先生担任分子诊断生命科学公司Cardiodx，Inc.的首席财务官，并于2014年4月至2016年7月担任Cardiodx董事会成员。Guggenhime从2010年9月到2011年4月担任Calistoga Pharmaceuticals，Inc.（一家生物技术公司，2011年4月被吉利德科学公司收购）首席财务官。Guggenhime从2008年12月到2010年6月担任Facet Biotech Corporation（一家生物技术公司，2010年4月被雅培公司收购）高级副总裁和首席财务官。Facet Biotech Corporation从PDLBioPharma，Inc.分拆出来，2006年4月至2008年12月，Guggenhime先生在该公司担任高级副总裁和首席财务官。2000年10月至2006年3月，Guggenhime先生担任Neoforma，Inc.的首席财务官，该公司是一家为梦百合行业提供供应链管理解决方案的供应商，于2006年3月被Global梦百合Exchange，LLC收购。2000年1月至10月，Guggenhime先生担任Neoforma’；s公司发展部的Vice President。Guggenhime先生的职业生涯始于美林公司（Merrill Lynch&Co.）和富国银行集团公司（Citigroup）的金融服务。Guggenhime先生拥有Middlebury College的国际政治和经济学学士学位，并持有西北大学J.L.Kellogg管理研究生院的工商管理硕士学位。
- Andrew Guggenhime has served on our board of directors since April 2021. Mr. Guggenhime currently serves as the President and Chief Financial Officer at Vaxcyte, Inc., positions he has held since December and May 2020 respectively. Prior to joining Vaxcyte, he served as Chief Financial Officer of Dermira, Inc. from April 2014 through the acquisition of the company by Eli Lilly and Company in February 2020. Prior to Dermira, Mr. Guggenhime served as Chief Financial Officer for CardioDx, Inc. from September 2011 to April 2014 and as a director of the company from April 2014 to July 2016. He also served as Chief Financial Officer for Calistoga Pharmaceuticals, Inc., from September 2010 to April 2011 which was acquired by Gilead Sciences, Inc. in 2011 and as Chief Financial Officer for Facet Biotech Corporation, from December 2008 to June 2010 which was acquired by Abbott Laboratories in April 2010. Mr. Guggenhime previously served as Chief Financial Officer of PDL BioPharma, Inc., until Facet Biotech was spun off from PDL BioPharma in December 2008. Prior to joining Facet Biotech, he served as Chief Financial Officer for Neoforma, Inc., which was acquired by Global Healthcare Exchange, LLC in March 2006. Mr. Guggenhime began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company. He received his B.A. in international politics and economics from Middlebury College and his M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University.
- Jim Wassil
Jim Wassil自2019年12月1日起担任我们的首席运营官。2015年5月至2019年12月，Wassil先生担任跨国制药公司辉瑞公司（McKinsey）Vice President兼全球健康和价值业务主管。2008年8月至2015年5月，Wassil先生担任跨国制药公司Novartis AG全球产品开发脑膜炎球菌疫苗主管和美国脑膜炎球菌疫苗营销主管。在加入诺华公司之前，瓦西尔先生曾担任跨国制药公司默克制药公司公司的国际营销高级总监。Wassil先生是美国传染病学会（Infective Diseases Society of America）的成员。Wassil先生拥有圣母大学（University of Notre Dame）的化学/生物学学士学位和利哈伊大学（Lehigh University）的生物有机化学硕士学位和工商管理硕士学位。
Jim Wassil has served as our Chief Operating Officer since December 1 2019. From May 2015 to December 2019 Mr. Wassil served as Vice President and Global Health and Value Business Unit Lead, Vaccines at Pfizer Inc., a multinational pharmaceutical company. From August 2008 to May 2015 Mr. Wassil served as Head, Global Product Development Meningococcal Vaccines and Head, U.S. Marketing for Meningococcal Vaccines at Novartis AG, a multinational pharmaceutical company. Prior to joining Novartis, Mr. Wassil served as Senior Director, International Marketing at Merck & Co., Inc., a multinational pharmaceutical company. Mr. Wassil is a member of the Infectious Diseases Society of America. Mr. Wassil holds a B.S. in Chemistry/Biology from the University of Notre Dame and a M.S. in BioOrganic Chemistry and an M.B.A. from Lehigh University.- Jim Wassil自2019年12月1日起担任我们的首席运营官。2015年5月至2019年12月，Wassil先生担任跨国制药公司辉瑞公司（McKinsey）Vice President兼全球健康和价值业务主管。2008年8月至2015年5月，Wassil先生担任跨国制药公司Novartis AG全球产品开发脑膜炎球菌疫苗主管和美国脑膜炎球菌疫苗营销主管。在加入诺华公司之前，瓦西尔先生曾担任跨国制药公司默克制药公司公司的国际营销高级总监。Wassil先生是美国传染病学会（Infective Diseases Society of America）的成员。Wassil先生拥有圣母大学（University of Notre Dame）的化学/生物学学士学位和利哈伊大学（Lehigh University）的生物有机化学硕士学位和工商管理硕士学位。
- Jim Wassil has served as our Chief Operating Officer since December 1 2019. From May 2015 to December 2019 Mr. Wassil served as Vice President and Global Health and Value Business Unit Lead, Vaccines at Pfizer Inc., a multinational pharmaceutical company. From August 2008 to May 2015 Mr. Wassil served as Head, Global Product Development Meningococcal Vaccines and Head, U.S. Marketing for Meningococcal Vaccines at Novartis AG, a multinational pharmaceutical company. Prior to joining Novartis, Mr. Wassil served as Senior Director, International Marketing at Merck & Co., Inc., a multinational pharmaceutical company. Mr. Wassil is a member of the Infectious Diseases Society of America. Mr. Wassil holds a B.S. in Chemistry/Biology from the University of Notre Dame and a M.S. in BioOrganic Chemistry and an M.B.A. from Lehigh University.
- Paul Sauer
自2016年4月以来，Paul Sauer一直担任我们的高级副总裁，工艺开发和制造。从2015年1月至2016年3月，Sauer先生担任Sauer Biotech Consulting（一家开发和制造咨询服务公司）的负责人。Sauer从2011年7月到2014年12月担任生物技术公司Igencia Biotherapeutics，Inc.流程科学和制造Vice President。Sauer先生拥有加州大学戴维斯分校（University of California，Davis）的遗传学学士学位和心理学学士学位，以及圣克拉拉大学（Santa Clara University）的工商管理硕士学位。
Paul Sauer has served as our Senior Vice President, Process Development and Manufacturing since April 2016. From January 2015 to March 2016 Mr. Sauer served as a Principal at Sauer Biotech Consulting, a development and manufacturing consulting services firm. From July 2011 to December 2014 Mr. Sauer served as Vice President, Process Sciences and Manufacturing at Igencia Biotherapeutics, Inc., a biotechnology company. Mr. Sauer holds a B.S. in Genetics and a B.A. in Psychology from the University of California, Davis and an M.B.A. from Santa Clara University.- 自2016年4月以来，Paul Sauer一直担任我们的高级副总裁，工艺开发和制造。从2015年1月至2016年3月，Sauer先生担任Sauer Biotech Consulting（一家开发和制造咨询服务公司）的负责人。Sauer从2011年7月到2014年12月担任生物技术公司Igencia Biotherapeutics，Inc.流程科学和制造Vice President。Sauer先生拥有加州大学戴维斯分校（University of California，Davis）的遗传学学士学位和心理学学士学位，以及圣克拉拉大学（Santa Clara University）的工商管理硕士学位。
- Paul Sauer has served as our Senior Vice President, Process Development and Manufacturing since April 2016. From January 2015 to March 2016 Mr. Sauer served as a Principal at Sauer Biotech Consulting, a development and manufacturing consulting services firm. From July 2011 to December 2014 Mr. Sauer served as Vice President, Process Sciences and Manufacturing at Igencia Biotherapeutics, Inc., a biotechnology company. Mr. Sauer holds a B.S. in Genetics and a B.A. in Psychology from the University of California, Davis and an M.B.A. from Santa Clara University.
- Jeff Fairman
Jeff Fairman是我们的联合创始人，自2013年12月以来一直担任我们的研究Vice President。Fairman从2011年7月到2013年12月担任生物制药公司Colby Pharmaceuticals研究Vice President。Fairman先生还创立了生物制药公司Juvaris Biotherapeutics，Inc.，并于2002年2月至2011年9月担任其研究Vice President。Fairman先生是美国免疫学家协会（American Association of Immunologists）和美国传染病学会（Infective Diseases Society of America）的成员。Fairman先生拥有西北密苏里州立大学（Northwest Missouri State University）的化学学士学位和阿肯色大学（University of Arkansas）的化学博士学位。
Jeff Fairman is our co-founder and has served as our Vice President, Research since December 2013. From July 2011 to December 2013 Mr. Fairman served as Vice President, Research at Colby Pharmaceuticals, a biopharmaceutical company. Mr. Fairman also founded Juvaris BioTherapeutics, Inc., a biopharmaceutical company, and served as its Vice President, Research from February 2002 to September 2011. Mr. Fairman is a member of the American Association of Immunologists and the Infectious Diseases Society of America. Mr. Fairman holds a B.S. in Chemistry from Northwest Missouri State University and a Ph.D. in Chemistry from the University of Arkansas.- Jeff Fairman是我们的联合创始人，自2013年12月以来一直担任我们的研究Vice President。Fairman从2011年7月到2013年12月担任生物制药公司Colby Pharmaceuticals研究Vice President。Fairman先生还创立了生物制药公司Juvaris Biotherapeutics，Inc.，并于2002年2月至2011年9月担任其研究Vice President。Fairman先生是美国免疫学家协会（American Association of Immunologists）和美国传染病学会（Infective Diseases Society of America）的成员。Fairman先生拥有西北密苏里州立大学（Northwest Missouri State University）的化学学士学位和阿肯色大学（University of Arkansas）的化学博士学位。
- Jeff Fairman is our co-founder and has served as our Vice President, Research since December 2013. From July 2011 to December 2013 Mr. Fairman served as Vice President, Research at Colby Pharmaceuticals, a biopharmaceutical company. Mr. Fairman also founded Juvaris BioTherapeutics, Inc., a biopharmaceutical company, and served as its Vice President, Research from February 2002 to September 2011. Mr. Fairman is a member of the American Association of Immunologists and the Infectious Diseases Society of America. Mr. Fairman holds a B.S. in Chemistry from Northwest Missouri State University and a Ph.D. in Chemistry from the University of Arkansas.